Background: We evaluated the effectiveness and safety of a zotarolimus-eluting (ZES) versus a sirolimus-eluting (SES) coronary stent in a large cohort of patients treated with one of these stents in Western Denmark.Methods: A total of 6,122 patients treated with ZES (n=2,282) or SES (n=3,840) were followed for up to 27 months. We ascertained clinical outcomes based on national medical databases.Results: Incidence of target lesion revascularization (no. per 100 person-years) was 5.3 in the ZES group compared to 1.9 in the SES group (adjusted hazard ratio (HR)=2.19, 95% confidence intervals (CI): 1.39-3.47; p=0.001). All-cause mortality was also higher in the ZES group (ZES: 6.3; SES: 3.3; adjusted HR=1.34, 95% CI: 1.05-1.72; p=0.02), while stent thrombosis (ZES: 1.2; SES: 0.5; adjusted HR=1.98, 95% CI: 0.75-5.23; p=0.14) did not differ significantly.Conclusions: In agreement with previously published randomised data, this observational study indicated that the ZES was associated with an increased risk of death and TLR in a large cohort of consecutive patients. © 2012 Maeng et al.; licensee BioMed Central Ltd.
CITATION STYLE
Maeng, M., Jensen, L. O., Kaltoft, A., Tilsted, H. H., Christiansen, E. H., Thayssen, P., … Thuesen, L. (2012). Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: A study from the Western Denmark Heart Registry. BMC Cardiovascular Disorders, 12. https://doi.org/10.1186/1471-2261-12-84
Mendeley helps you to discover research relevant for your work.